AI-Mind
SESSION

17 October 2023
14:00 - 15:15
Room 207 (first floor)

The potential of artificial intelligence (AI) for dementia risk prediction

AI-Mind: a new pathway for identifying mild cognitive impairment and opening a window of therapeutic possibilities
Speaker: Dr. Ira Haraldsen, Norway

Opportunities created by Artificial Intelligence (AI) in dementia research and diagnosis
Speaker: Dr. Ainar Drews, Norway

The potential value of a dementia risk estimation tool for people with mild cognitive impairment (MCI): an early Health Technology Assessment (HTA)
Speaker: Robin Vermeulen, Netherlands

What do we know about patient perception of artificial intelligence?
Speaker: Eugenio Di Brino, Italy

Learn more about the programme & speakers

Who should join?

The AI-Mind session is dedicated to all interested in learning more about MCI, screening methods and opportunities created by using AI for the prediction, research and diagnosis of dementia as well as ethical implications.



AI-Mind speakers

Dr. Ira Haraldsen

Dr. Ira Hebold Haraldsen, the AI-Mind project coordinator, is a translational researcher focusing on the neuroendocrine control of brain development and cognitive functions in different species. Her investigative approach is collaborative and interdisciplinary, spanning the fields of human neuroendocrinology and neuropsychology, molecular biology, and PET tracer development.

OSLO UNIVERSITETSSYKEHUS

Dr. Ainar Drews

Dr. Drews is the technical coordination manager of the AI-Mind consortium, managing the inter-disciplinary coordination of clinicians, developers and AI researchers. The project aims to develop artificial intelligence tools to study and reliably predict the progression to dementia in people diagnosed with mild cognitive impairment.

Robin Vermeulen

Robin Vermeulen has a background in Biomedical Sciences, specifically in the field of (early) Health Technology Assessment. Currently, she is a PhD candidate at the Radboud University Medical Center. Robin's research aims to study the potential added value of healthcare innovations in the early stages of development, to be able to inform about the potential cost-effectiveness of these innovations and to help steer the further developments.

Radboudumc
university medical center

Eugenio Di Brino

Eugenio Di Brino, a health economist at Università Cattolica del Sacro Cuore, specialised in pharmacoeconomics, health technology assessment (HTA), and patient involvement. With extensive academic and research experience since 2015, Eugenio also coordinates master's programs and the Patient Advocacy Lab at ALTEMS. He also holds key positions in various health organisations and contributes to European projects.

UNIVERSITÀ CATTOLICA del Sacro Cuore

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 964220. This flyer reflects only the AI-Mind consortium view and the Commission is not responsible for any use that may be made of the information it contains.